<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02075125</url>
  </required_header>
  <id_info>
    <org_study_id>PANTASTIC</org_study_id>
    <nct_id>NCT02075125</nct_id>
  </id_info>
  <brief_title>Prasugrel and Ticagrelor in ST-segment Elevation Myocardial Infarction</brief_title>
  <official_title>Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-segment Elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare efficacy and safety of prasugrel and ticagrelor in patients with ST-segment
      elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prasugrel and ticagrelor are recommended in patients with ST-segment elevation myocardial
      infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). Both
      prasugrel and ticagrelor show more rapid and potent antiplatelet effect compared with
      clopidogrel. However, previous report comparing the efficacy and safety of prasugrel and
      ticagrelor in patients with STEMI of East Asian ethnicity is lacking. Therefore, the aim of
      this study is to compare the antiplatelet efficacy and safety using laboratory platelet
      function tests and clinical outcomes in patients with STEMI treated with either prasugrel or
      ticagrelor.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enrolling participants has halted prematurely and will not resume
  </why_stopped>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With High Platelet Reactivity</measure>
    <time_frame>48 hours after loading dose of study drug</time_frame>
    <description>Platelet reactivity were measured by VerifyNow (volumetrics accuretic，San Diego, California, USA), and vasodilator-stimulated phosphoprotein (VASP) phosphorylation P2Y12 assay (BioCytex, Marseille, France) with FACSCalibur flow cytometer (BD Biosciences, San Jose, California, USA) using. Measurement time gap +/- 12 hours were allowed. High platelet reactivity (HPR) is defined as the result of P2Y12 reaction units (PRU) &gt;235 and platelet reactivity index (PRI) &gt;50%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac and Cerebrovascular Events</measure>
    <time_frame>30 days</time_frame>
    <description>Any major adverse cardiac and cerebrovascular event including (death, myocardial infarction, or revascularization and stroke) until day 30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Event</measure>
    <time_frame>30 days</time_frame>
    <description>Any event related to bleeding including access site bleeding and peri-procedural bleeding based on Bleeding Academic Research Consortium (BARC) criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Drug Reaction</measure>
    <time_frame>30 days</time_frame>
    <description>Any adverse reaction related to study drug until 30 days after percutaneous coronary intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-procedure P2Y12 Reaction Units (PRU)</measure>
    <time_frame>Baseline</time_frame>
    <description>Platelet reactivity was measured using VerifyNow (volumetrics accuretic, San Diego, California, USA). Platelet reactivity values were presented as P2Y12 reaction units (PRU).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Low Platelet Reactivity</measure>
    <time_frame>48 hours after loading dose of study drug</time_frame>
    <description>Platelet reactivity were measured using VerifyNow (volumetrics accuretic, San Diego, California, USA), and vasodilator-stimulated phosphoprotein (VASP) phosphorylation P2Y12 assay (BioCytex, Marseille, France) with FACSCalibur flow cytometer (BD Biosciences, San Jose, California, USA) using. Measurement time gap +/- 12 hours were allowed. Low platelet reactivity (LPR) is defined as the result of P2Y12 reaction units (PRU) &lt;85 and platelet reactivity index (PRI)&lt;16%. The PRU value for LPR, 18 patients were in prasugrel groups and 19 patients in ticagrelor groups, regarding the PRI value for LPR, 16 patients were in each groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-procedure Platelet Reactivity Index (PRI)</measure>
    <time_frame>Baseline</time_frame>
    <description>Platelet reactivity was measured using vasodilator-stimulated phosphoprotein (VASP) phosphorylation P2Y12 assay. Platelet reactivity values were presented as platelet reactivity index (PRI).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>ST-Segment Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Prasugrel 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prasugrel 60 mg as loading dose and followed by 10 mg/day as maintenance dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor 180 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor 180 mg as loading dose and followed by 90 mg twice a day as maintenance dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel 60 mg</intervention_name>
    <description>Patient administer prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose.</description>
    <arm_group_label>Prasugrel 60 mg</arm_group_label>
    <other_name>Effient 60 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor 180 mg</intervention_name>
    <description>Patients administer ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose.</description>
    <arm_group_label>Ticagrelor 180 mg</arm_group_label>
    <other_name>Brilinta 180 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with ST-segment elevation myocardial infarction

          -  Undergoing primary percutaneous coronary intervention

          -  Aged between 20 and 80 years

        Exclusion Criteria:

          -  Previous administration of any antagonist of the platelet adenosine diphosphate (ADP)
             P2Y12 receptor (clopidogrel, prasugrel or ticagrelor)

          -  History of stroke or transient ischemic attack

          -  Previous gastrointestinal bleeding within 6 months, bleeding diathesis, platelet count
             &lt; 100,000/mm3 or hemoglobin &lt; 10 g/dl

          -  Chronic oral anticoagulation treatment

          -  Contraindication to the antiplatelet treatment

          -  Severe renal insufficiency (serum creatine&gt;2.5 mg/dl)

          -  Severe hepatic dysfunction (serum liver enzyme or bilirubin&gt;3 times normal limit)

          -  Sever chronic obstructive pulmonary disease (COPD) or bradycardia

          -  Body weight &lt; 50 kg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moo Hyun Kim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dong-A University Hospital, Busan, Republic of Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DongA University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>602-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Parodi G, Valenti R, Bellandi B, Migliorini A, Marcucci R, Comito V, Carrabba N, Santini A, Gensini GF, Abbate R, Antoniucci D. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol. 2013 Apr 16;61(15):1601-6. doi: 10.1016/j.jacc.2013.01.024. Epub 2013 Mar 22.</citation>
    <PMID>23500251</PMID>
  </reference>
  <reference>
    <citation>Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, Koutsogiannis N, Damelou A, Tsigkas G, Davlouros P, Hahalis G. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2012 Dec;5(6):797-804. doi: 10.1161/CIRCINTERVENTIONS.112.972323. Epub 2012 Nov 20.</citation>
    <PMID>23169985</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2014</study_first_submitted>
  <study_first_submitted_qc>February 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2014</study_first_posted>
  <results_first_submitted>September 13, 2015</results_first_submitted>
  <results_first_submitted_qc>December 24, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 1, 2016</results_first_posted>
  <last_update_submitted>July 11, 2017</last_update_submitted>
  <last_update_submitted_qc>July 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dong-A University</investigator_affiliation>
    <investigator_full_name>Moo Hyun Kim</investigator_full_name>
    <investigator_title>M.D. Director, Global Clinical Trial Center. Professor, Dept. of Cardiology Dong-A Unicersity Hospital</investigator_title>
  </responsible_party>
  <keyword>Korea</keyword>
  <keyword>Platelet inhibition</keyword>
  <keyword>Prasugrel</keyword>
  <keyword>Ticagrelor</keyword>
  <keyword>ST-segment elevation myocardial infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Prasugrel</title>
          <description>Patient administer Prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose.</description>
        </group>
        <group group_id="P2">
          <title>Ticagrelor</title>
          <description>Patient administer Ticagrelor 180 mg as loading dose followed by 90 mg twice a day as maintenance dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19">One patient switched to clopidogrel treatment after 18 days of ticagrelor treatment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Prasugrel</title>
          <description>Patient administer Prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose.</description>
        </group>
        <group group_id="B2">
          <title>Ticagrelor</title>
          <description>Patients administer Ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" spread="10"/>
                    <measurement group_id="B2" value="55" spread="11"/>
                    <measurement group_id="B3" value="55" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.3" spread="2.7"/>
                    <measurement group_id="B2" value="24.4" spread="2.4"/>
                    <measurement group_id="B3" value="24.9" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With High Platelet Reactivity</title>
        <description>Platelet reactivity were measured by VerifyNow (volumetrics accuretic，San Diego, California, USA), and vasodilator-stimulated phosphoprotein (VASP) phosphorylation P2Y12 assay (BioCytex, Marseille, France) with FACSCalibur flow cytometer (BD Biosciences, San Jose, California, USA) using. Measurement time gap +/- 12 hours were allowed. High platelet reactivity (HPR) is defined as the result of P2Y12 reaction units (PRU) &gt;235 and platelet reactivity index (PRI) &gt;50%.</description>
        <time_frame>48 hours after loading dose of study drug</time_frame>
        <population>Analysis population was performed on an intention to treat basis, descriptive analysis was performed by presenting the data as number (proportion), compared with chi-square statistics or Fisher’s exact test, as appropriate.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel</title>
            <description>Patient administer prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor</title>
            <description>Patients administer ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With High Platelet Reactivity</title>
          <description>Platelet reactivity were measured by VerifyNow (volumetrics accuretic，San Diego, California, USA), and vasodilator-stimulated phosphoprotein (VASP) phosphorylation P2Y12 assay (BioCytex, Marseille, France) with FACSCalibur flow cytometer (BD Biosciences, San Jose, California, USA) using. Measurement time gap +/- 12 hours were allowed. High platelet reactivity (HPR) is defined as the result of P2Y12 reaction units (PRU) &gt;235 and platelet reactivity index (PRI) &gt;50%.</description>
          <population>Analysis population was performed on an intention to treat basis, descriptive analysis was performed by presenting the data as number (proportion), compared with chi-square statistics or Fisher’s exact test, as appropriate.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PRU&gt;235</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VASP-PRI&gt;50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Adverse Cardiac and Cerebrovascular Events</title>
        <description>Any major adverse cardiac and cerebrovascular event including (death, myocardial infarction, or revascularization and stroke) until day 30.</description>
        <time_frame>30 days</time_frame>
        <population>Analysis population was performed on an intention to treat basis, descriptive analysis was performed by presenting the data as number (proportion), compared with chi-square statistics or Fisher’s exact test, as appropriate.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel</title>
            <description>Patient administer prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor</title>
            <description>Patients administer ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Cardiac and Cerebrovascular Events</title>
          <description>Any major adverse cardiac and cerebrovascular event including (death, myocardial infarction, or revascularization and stroke) until day 30.</description>
          <population>Analysis population was performed on an intention to treat basis, descriptive analysis was performed by presenting the data as number (proportion), compared with chi-square statistics or Fisher’s exact test, as appropriate.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding Event</title>
        <description>Any event related to bleeding including access site bleeding and peri-procedural bleeding based on Bleeding Academic Research Consortium (BARC) criteria.</description>
        <time_frame>30 days</time_frame>
        <population>Analysis population was performed on an intention to treat basis, descriptive analysis was performed by presenting the data as number (proportion), compared with chi-square statistics or Fisher’s exact test, as appropriate.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel</title>
            <description>Patient administer prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor</title>
            <description>Patients administer ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Event</title>
          <description>Any event related to bleeding including access site bleeding and peri-procedural bleeding based on Bleeding Academic Research Consortium (BARC) criteria.</description>
          <population>Analysis population was performed on an intention to treat basis, descriptive analysis was performed by presenting the data as number (proportion), compared with chi-square statistics or Fisher’s exact test, as appropriate.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Drug Reaction</title>
        <description>Any adverse reaction related to study drug until 30 days after percutaneous coronary intervention.</description>
        <time_frame>30 days</time_frame>
        <population>Analysis population was performed on an intention to treat basis, descriptive analysis was performed by presenting the data as number, compared with chi-square statistics or Fisher’s exact test, as appropriate.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel</title>
            <description>Patient administer prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor</title>
            <description>Patients administer ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Drug Reaction</title>
          <description>Any adverse reaction related to study drug until 30 days after percutaneous coronary intervention.</description>
          <population>Analysis population was performed on an intention to treat basis, descriptive analysis was performed by presenting the data as number, compared with chi-square statistics or Fisher’s exact test, as appropriate.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-procedure P2Y12 Reaction Units (PRU)</title>
        <description>Platelet reactivity was measured using VerifyNow (volumetrics accuretic, San Diego, California, USA). Platelet reactivity values were presented as P2Y12 reaction units (PRU).</description>
        <time_frame>Baseline</time_frame>
        <population>Analysis population was performed on an intention to treat basis, descriptive analysis was performed by presenting the data as median (Inter-Quartile Range).</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel</title>
            <description>Patient administer prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor</title>
            <description>Patients administer ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-procedure P2Y12 Reaction Units (PRU)</title>
          <description>Platelet reactivity was measured using VerifyNow (volumetrics accuretic, San Diego, California, USA). Platelet reactivity values were presented as P2Y12 reaction units (PRU).</description>
          <population>Analysis population was performed on an intention to treat basis, descriptive analysis was performed by presenting the data as median (Inter-Quartile Range).</population>
          <units>PRU units</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259" lower_limit="230" upper_limit="281"/>
                    <measurement group_id="O2" value="261" lower_limit="196" upper_limit="286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Low Platelet Reactivity</title>
        <description>Platelet reactivity were measured using VerifyNow (volumetrics accuretic, San Diego, California, USA), and vasodilator-stimulated phosphoprotein (VASP) phosphorylation P2Y12 assay (BioCytex, Marseille, France) with FACSCalibur flow cytometer (BD Biosciences, San Jose, California, USA) using. Measurement time gap +/- 12 hours were allowed. Low platelet reactivity (LPR) is defined as the result of P2Y12 reaction units (PRU) &lt;85 and platelet reactivity index (PRI)&lt;16%. The PRU value for LPR, 18 patients were in prasugrel groups and 19 patients in ticagrelor groups, regarding the PRI value for LPR, 16 patients were in each groups.</description>
        <time_frame>48 hours after loading dose of study drug</time_frame>
        <population>Analysis population was performed on an intention to treat basis, descriptive analysis was performed by presenting the data as number (proportion), compared with chi-square statistics or Fisher’s exact test, as appropriate.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel</title>
            <description>Patient administer prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor</title>
            <description>Patients administer ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Low Platelet Reactivity</title>
          <description>Platelet reactivity were measured using VerifyNow (volumetrics accuretic, San Diego, California, USA), and vasodilator-stimulated phosphoprotein (VASP) phosphorylation P2Y12 assay (BioCytex, Marseille, France) with FACSCalibur flow cytometer (BD Biosciences, San Jose, California, USA) using. Measurement time gap +/- 12 hours were allowed. Low platelet reactivity (LPR) is defined as the result of P2Y12 reaction units (PRU) &lt;85 and platelet reactivity index (PRI)&lt;16%. The PRU value for LPR, 18 patients were in prasugrel groups and 19 patients in ticagrelor groups, regarding the PRI value for LPR, 16 patients were in each groups.</description>
          <population>Analysis population was performed on an intention to treat basis, descriptive analysis was performed by presenting the data as number (proportion), compared with chi-square statistics or Fisher’s exact test, as appropriate.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PRU&lt;85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VASP-PRI&lt;16%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-procedure Platelet Reactivity Index (PRI)</title>
        <description>Platelet reactivity was measured using vasodilator-stimulated phosphoprotein (VASP) phosphorylation P2Y12 assay. Platelet reactivity values were presented as platelet reactivity index (PRI).</description>
        <time_frame>Baseline</time_frame>
        <population>Analysis population was performed on an intention to treat basis, descriptive analysis was performed by presenting the data as median (Inter-Quartile Range).</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel</title>
            <description>Patient administer prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose.</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor</title>
            <description>Patients administer ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-procedure Platelet Reactivity Index (PRI)</title>
          <description>Platelet reactivity was measured using vasodilator-stimulated phosphoprotein (VASP) phosphorylation P2Y12 assay. Platelet reactivity values were presented as platelet reactivity index (PRI).</description>
          <population>Analysis population was performed on an intention to treat basis, descriptive analysis was performed by presenting the data as median (Inter-Quartile Range).</population>
          <units>percentage</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.2" lower_limit="39.3" upper_limit="61.3"/>
                    <measurement group_id="O2" value="47.5" lower_limit="38.4" upper_limit="50.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Prasugrel</title>
          <description>Patient administer prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose.</description>
        </group>
        <group group_id="E2">
          <title>Ticagrelor</title>
          <description>Patients administer ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2.5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>For the present single-center pilot study, the small sample size was a major limitation, and as such was insufficiently powered to assess safety.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Moo Hyun Kim; Director of Global Clinical Trial Center Dong-A University Hospital.</name_or_title>
      <organization>Department of Cardiology, College of Medicine, Dong-A University.</organization>
      <phone>+82 (51) 240-2976</phone>
      <email>kimmh@dau.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

